China’s health insurance regulator in October added 17 anti-cancer drugs to the list of those already covered by its national medical insurance system. The approval of the therapies is part of a series of moves by the government to make cancer treatment... Read More
Driven by economic growth and expanding access to healthcare, the in-vitro diagnostics (IVD) market is rapidly expanding across the Asia-Pacific region. With an aging population, the region is experiencing significant rise in chronic conditions that can be diagnosed and monitored using IVD... Read More
According to Galen Growth Asia, Asian healthcare funding rose significantly in the third quarter of 2018. There were 78 deals done in the third quarter for about $1.4 billion. They expect healthcare funding deals to total about $6 billion in 2018. There... Read More
Moving to counter widespread criticism that its drug supply chain is unsafe and inefficient, Chinese health officials are moving to modernize the nation’s system for tracing pharmaceuticals. In a flurry of recent moves, the China National Drug Administration (CNDA) has posted draft... Read More
The US government is now determining whether Chinese investment into certain industries jeopardizes US intellectual property. In addition to about 25 other industries, biotech companies may now be reviewed by the committee for foreign investment into the US even with respect to... Read More
In an effort to streamline its drug approval process, the Chinese government will expedite the review of 48 urgently needed drugs already approved outside of China. Under these eased requirements announced in August, the China National Drug Administration (CNDA) will waive the... Read More
Renewing medical device registrations in China just became more simple. Moving to expedite the introduction of important new technologies to market, regulators announced this summer that they will require less documentation on sales data and post-market inspection reports from device makers seeking... Read More
As the pharmaceutical industry’s expansion into emerging markets meets the desire of Asian governments to speed approval of innovative products, demand for clinical trials is soaring in the Asian region. By 2021, the global market for clinical trials is expected to reach... Read More
On August 3, in response to the Trump administration’s threats to add $200 billion of tariffs on Chinese goods, the Chinese Ministry of Commerce announced that they will tax 5% to 25% on an additional $60 billion worth of U.S. goods. The... Read More
Last month, the China National Drug Administration (CNDA), formerly known as the China Food and Drug Administration (CFDA), released a fourth batch of Class II and III medical devices that may be exempted from the requirement to conduct local clinical studies to... Read More